About this medicine

Acamprosate supports recovery after stopping alcohol. It is used with counselling and does not cancel the physical harms of continued drinking.

Recovery involves more than preventing a drink on a particular day. Counselling, practical support and an agreed plan for lapses remain important while the medicine is prescribed. The UK Campral EC product remains distinct from the discontinued American Campral brand record; a commercial change in one country does not determine the other country's product status.

What is this medicine used for?

Campral EC is licensed to maintain abstinence in alcohol dependence. NICE includes it with psychological treatment after successful withdrawal, following medical assessment.

Which warning signs need help?

Acamprosate is not a treatment for acute withdrawal. Seizures, severe confusion or hallucinations after reducing alcohol need emergency help. Facial or throat swelling with breathing difficulty also requires immediate care: 999 in the UK, local emergency services elsewhere.

Mood and suicidal thinking also require monitoring during alcohol recovery. New or worsening thoughts of self-harm need urgent support; immediate danger requires emergency help in the country where the person is physically present.

How do I take it safely?

For adults aged 18–65 weighing at least 60 kg, the checked label uses two 333 mg tablets three times daily with meals. Below 60 kg it uses two in the morning, one at noon and one at night. These are label schedules, not personal instructions.

Start timing must distinguish the licence from specialist practice. Campral's licence describes starting after withdrawal when abstinent. DHSC guidance also discusses starting during medically assisted withdrawal as off-label practice; this does not make acamprosate a treatment for withdrawal symptoms.

What side effects should I know about?

Diarrhoea is very common. Abdominal pain, nausea, wind, vomiting, itching and rash can occur. Persistent symptoms should be discussed with the prescriber.

Keep the care team informed if diarrhoea or vomiting disrupts drinking fluids or taking treatment. A common adverse effect can still be important when it interferes with daily life or recovery.

Who needs extra care with this medicine?

The Campral label contraindicates renal insufficiency above its specified serum-creatinine threshold. Severe liver disease has limited safety evidence. A clinician must assess suitability before prescribing.

The checked Campral contraindication uses serum creatinine above 120 micromol/L. This is not interchangeable with the American creatinine-clearance thresholds. DHSC discusses renal prescribing outside the product restriction; such decisions require specialist judgement and are not a home dose-reduction rule.

Can it affect my other medicines?

A pharmacist should check all medicines. The generic label identifies potential interactions involving kidney secretion and reports worsening angina with diltiazem; compatible trial combinations do not make every combination safe.

An interaction check considers effects on the kidneys and the person's other illnesses, not just liver enzymes. Do not add a second alcohol-treatment medicine because a study allowed a combination.

What check-ups will I need?

Assess physical health and kidney and liver tests before starting. Review mood, adherence, adverse effects and drinking outcomes alongside psychological care.

Review should cover mood, drinking outcomes, adverse effects, weight-related dosing and practical adherence. DHSC does not require repeated blood tests for everyone with acceptable baseline results; changes in health can still justify further assessment.

What about pregnancy, breastfeeding and age?

The label does not recommend use below 18 or above 65 and contraindicates breastfeeding. Pregnancy requires careful assessment of medicine risks and the risks of ongoing alcohol use.

What if I miss a dose or want to stop?

Do not double a forgotten dose. Follow the supplied leaflet and ask the treatment team before stopping. The treatment plan may continue after a lapse, while persistent drinking requires review of benefit and support.

A lapse and persistent drinking are different circumstances. Tell the team so they can reassess safety, benefit and the recovery plan. The product recommends a year of treatment; DHSC describes review-based prescribing, commonly six months with extension when helpful. Neither duration should be selected independently.

How does it work?

Acamprosate appears to influence the way brain cells communicate after prolonged alcohol exposure. Two important messengers are glutamate, which often makes a receiving cell more likely to become active, and GABA, which often restrains that activity. These are called excitatory and inhibitory signals, and both are normal parts of brain function.

Repeated alcohol exposure can lead the brain to adapt across these connected systems. Laboratory and animal findings suggest that acamprosate affects glutamate-related and GABA-related signaling, but the exact process that explains its benefit in maintaining abstinence, a period without drinking, is not fully understood. Describing it as a possible influence on these adaptations is more accurate than claiming it corrects a chemical level measured in an individual.

How does it affect my body?

The aim is to support abstinence, not to produce a disulfiram-like reaction to alcohol. A lapse should prompt contact with the care team rather than abandoning recovery support.

How does my body process it?

Absorption is relatively low and variable. Acamprosate undergoes little metabolism and is eliminated through urine; reduced kidney function can change its handling substantially.

The Campral label reports that usual absorption is below 10% during the first 24 hours and concentrations stabilise after about a week of regular dosing. The lack of substantial liver metabolism does not remove the need to assess liver disease and overall health.

How do treatment options differ?

Acamprosate and naltrexone are different relapse-prevention options. Disulfiram instead deters drinking through an alcohol reaction. A clinical assessment, not an online comparison, determines suitability.

A closer look at the science

Acamprosate is structurally related to amino-acid signalling compounds. The label proposes effects on inhibitory GABA signalling and excitatory glutamate pathways; these remain a mechanistic explanation rather than a diagnostic test.

The name acamprosate calcium describes a salt, not a calcium supplement. Product strength is expressed using that salt: the same tablet can be described as 333 mg of acamprosate calcium or 300 mg of acamprosate. These are two descriptions of its composition, not two different tablet doses.

How was this medicine developed?

The UK Campral EC record lists first authorisation in December 1995. Its SmPC was revised in August 2026.

The UK authorisation predates the American approval discussed in the USA edition. Historical approval, current product information and evidence for continuing benefit answer different questions; one does not replace the others.

Sources and References

  1. Campral EC 333 mg gastro-resistant tablets — patient leaflet, sections 1–4 and 6

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Campral EC — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. NICE CG115: alcohol-use disorders — pharmacological interventions, section 1.3.6

    Scope: NICE guidance (England-based); applicability and implementation in other UK nations require the relevant national pathway.

  4. NHS: alcohol-use disorder

    Scope: NHS.uk public information (England); not a statement of uniform services or funding across the four UK nations.

  5. Acamprosate 333 mg gastro-resistant tablets — SmPC, sections 4–5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Clinical guidelines for alcohol treatment, chapter 10: pharmacological interventions

    Scope: DHSC guidance; nation-specific implementation must be checked separately.

  7. Acamprosate calcium delayed-release tablets: current generic prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 11 Description; 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  8. Schizophrenia
  9. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top